Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

209.40
-1.7200-0.81%
Pre-market: 208.95-0.4500-0.21%04:04 EDT
Volume:5.65M
Turnover:1.19B
Market Cap:370.09B
PE:88.73
High:213.49
Open:211.42
Low:209.12
Close:211.12
52wk High:244.81
52wk Low:164.39
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.53
T/O Rate:0.32%
Dividend:6.65
Dividend Rate:3.18%
EPS(TTM):2.36
EPS(LYR):2.36
ROE:6225.00%
ROA:9.81%
PB:-113.18
PE(LYR):88.73

Loading ...

Abbvie Q4 Global Rinvoq Net Revenue $2.37 Bln VS Ibes Estimate $2.41 Bln

THOMSON REUTERS
·
Feb 04

Abbvie Q4 Global Rinvoq Revenue USD 2,374 Million

THOMSON REUTERS
·
Feb 04

Abbvie Q4 Global Skyrizi Revenue USD 5,006 Million

THOMSON REUTERS
·
Feb 04

Abbvie Q4 EPS USD 1.02

THOMSON REUTERS
·
Feb 04

Abbvie Reports Full-Year and Fourth-Quarter 2025 Financial Results

THOMSON REUTERS
·
Feb 04

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 04

What Are Good Stocks to Invest In Right Now?

TradingKey
·
Feb 04

U.S. Earnings Preview: Before Market Open Feb. 4

Dow Jones
·
Feb 04

Notable companies reporting before tomorrow’s open

TIPRANKS
·
Feb 04

AbbVie Expected to Swing to 4Q Profit as Revenue Climbs -- Earnings Preview

Dow Jones
·
Feb 04

AbbVie Seeks FDA Approval for Vitiligo Treatment

MT Newswires Live
·
Feb 03

Viatris Names Matthew J. Maletta Chief Legal Officer

Reuters
·
Feb 03

AbbVie Seeks Expanded U.S., Europe OK For Rinvoq in Vitiligo

Dow Jones
·
Feb 03

BRIEF-AbbVie Files FDA, EMA Applications For Rinvoq (Upadacitinib) For Adults, Teens With Vitiligo

Reuters
·
Feb 03

AbbVie Announces Positive Phase 3 Results for Upadacitinib in Non-Segmental Vitiligo

Reuters
·
Feb 03

Abbvie Submits Regulatory Applications to FDA and Ema for Upadacitinib (Rinvoq®) in Adults and Adolescents With Vitiligo

THOMSON REUTERS
·
Feb 03

Simcere Receives US$40 Million Milestone Payment From AbbVie for Multiple Myeloma Antibody SIM0500

TIPRANKS
·
Feb 03

Simcere Pharmaceutical Group erhält Meilensteinzahlung von AbbVie für SIM0500

Reuters
·
Feb 03

AbbVie Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Feb 03